Search International and National Patent Collections

1. (WO2018167104) FC-OPTIMIZED ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION

Pub. No.:    WO/2018/167104    International Application No.:    PCT/EP2018/056312
Publication Date: Fri Sep 21 01:59:59 CEST 2018 International Filing Date: Wed Mar 14 00:59:59 CET 2018
IPC: C07K 16/28
C07K 14/55
A61K 39/00
Applicants: TUSK THERAPEUTICS LTD
CANCER RESEARCH TECHNOLOGY LIMITED
Inventors: GOUBIER, Anne
MERCHIERS, Pascal
SALIMU, Josephine
GOYENECHEA, Beatriz
MOULDER, Kevin
QUEZADA, Sergio
PEGGS, Karl
VARGAS, Fred Arce
SOLOMON, Isabelle
Title: FC-OPTIMIZED ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION
Abstract:
The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2 - CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.